Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | PHGDH | O43175 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | ADH1C | P00326 | 2/20 | 0.44 |
| ▸ | ADH1A | P07327 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11078920 | 1.00 | ALDH1A1 (0.53) | ALDH1A1ATMFAAHPHGDHMGLL | |
| SCHEMBL11084903 | 1.00 | ALDH1A1 (0.53) | ALDH1A1ATMFAAHPHGDHMGLL | |
| Hydrochloric Acid SCHEMBL11628512 | 0.98 | ALDH1A1 (0.52) | ALDH1A1ATMFAAHPHGDHMGLL | |
| SCHEMBL965678 | 0.97 | ALDH1A1 (0.50) | ALDH1A1ATMFAAHPHGDHMGLL | |
| Hydrochloric Acid SCHEMBL11630431 | 0.95 | ALDH1A1 (0.48) | ALDH1A1ATMFAAHPHGDHMGLL | |
| SCHEMBL967360 | 0.95 | — | — | |
| SCHEMBL217412 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL4471911 | 0.84 | — | — | |
| SCHEMBL17704770 | 0.82 | FAAH (0.52) | ALDH1A1ATMFAAHPHGDHMGLL | |
| SCHEMBL434802 | 0.80 | ATM (0.50) | ALDH1A1ATMFAAHPHGDHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | claimed |
| CN-113993519-A | Degradation agent for cyclin dependent kinase 12(CDK12) and use thereof | 达纳-法伯癌症研究公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020123674-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-06-18 | — | — | WO | disclosed |
| CN-110753688-A | Compounds for the treatment of respiratory diseases | 墨尔本大学 | 2020-02-04 | — | — | CN | disclosed |
| US-10106526-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-10035777-B2 | Heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| US-10028920-B2 | Methods for treating occular irritation involving tearing by administering modulators of TRPM8 | UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (ES) | 2018-07-24 | — | — | US | disclosed |
| WO-2017130156-A1 | INGENOL ANALOGS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-08-03 | — | — | WO | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| EP-3177604-A1 | HETEROCYCLIC KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-2054055-A2 | COMBINATION FAAH INHIBITOR AND ANALGESIC, ANTI-INFLAMMATORY OR ANTI-PYRETIC AGENT | N.V. Organon (NL) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008021625-A2 | COMBINATION FAAH INHIBITOR AND ANALGESIC, ANTI-INFLAMMATORY OR ANTI-PYRETIC AGENT | N.V. ORGANON (NL) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045513-A1 | COMBINATION FAAH INHIBITOR AND ANALGESIC, ANTI-INFLAMMATORY OR ANTI-PYRETIC AGENT | N.V. ORGANON (NL) | 2008-02-21 | — | — | US | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| EP-0677040-B1 | PROCESS AND INTERMEDIATE PRODUCTS FOR PREPARING HYDROXYLAMINE-ETHERS AND THEIR SALTS | BASF AG (DE) | 1999-10-27 | — | — | EP | disclosed |
| US-5134151-A | Platelet Activating Factor Antagonist | J. URIACH & CIA (ES) | 1992-07-28 | — | — | US | disclosed |
| EP-0385490-A1 | 2-picolylamine derivates | J. URIACH & CIA. S.A. (ES) | 1990-09-05 | — | — | EP | disclosed |
| US-4426523-A | Preparation of 1-amino-1,3,5-triazine-2,4(1H, 3H)-diones | BAYER AKTIENGESELLSCHAFT (DE) | 1984-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | ALDH1A1 1036/4885ATM 600/4885FAAH 3547/4885 |
| US-10106526-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | ALDH1A1 3898/4885ATM 1067/4885FAAH 1337/4885 |
| US-20080045513-A1 | COMBINATION FAAH INHIBITOR AND ANALGESIC, ANTI-INFLAMMATORY OR ANTI-PYRETIC AGENT | FAAH, FAAH2, APEH | ALDH1A1 587/4885ATM 4476/4885FAAH 1/4885 |
| US-10028920-B2 | Methods for treating occular irritation involving tearing by administering modulators of TRPM8 | TRPM8, TRPM5, TRPM7 | ALDH1A1 3048/4885ATM 3476/4885FAAH 286/4885 |
| US-10035777-B2 | Heterocyclic kinase inhibitors | AAK1, NCK1, DAPK2 | ALDH1A1 3442/4885ATM 357/4885FAAH 2752/4885 |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | ALDH1A1 3898/4885ATM 1067/4885FAAH 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.